Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug
Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug
Read moreMon, 01st Feb 2021 13:20
Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug
Read moreAIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle
Read more(Sharecast News) - Clinical research organisation Open Orphan's hVIVO subsidiary has signed "a significant contract" to test AIM ImmunoTech's antiviral candidate, Ampligen.
Read more(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.
Read moreOpen Orphan reports widened 2020 loss; Poolbeg mulls London float
Read moreAIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough
Read moreUK earnings, trading statements calendar - next 7 days
Read moreTRADING UPDATES: Young's mulls asset sale; Ceres gets China investment
Read moreTRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid
Read more(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a contract with Imperial College London, as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.
Read moreEXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO
Read moreOpen Orphan launches new data platform to combat infectious diseases
Read moreTRADING UPDATES: Renew to buy J Browne; Idox in good start to year
Read moreTRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus
Read more(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.
Read more